Effect of long chain noncoding RNA BCYRN1 on malignant biological behavior of SKOV3 cells
-
摘要:
目的 探讨长链非编码RNA brain cytoplasmic RNA 1在卵巢癌组织中的表达及对SKOV3细胞恶性生物学行为的影响。 方法 选取温州市中心医院2017年3月—2019年3月收治的32例卵巢癌患者癌组织及其相应的癌旁组织标本，正常卵巢上皮细胞系IOSE和卵巢癌细胞系(SKOV3、HO8910、A2780)购自美国ATCC; 癌组织和癌细胞中BCYRN1的水平采用实时荧光定量法(qRT-PCR)检测; 采用BCYRN1高表达质粒和低表达质粒及其相应的对照物转染SKOV3细胞，分别构建BCYRN1高表达和低表达的细胞系; 采用BrdU法检测细胞的增殖; 采用划痕愈合实验检测细胞的迁移; 采用Transwell法检测细胞的侵袭。 结果 BCYRN1在卵巢癌组织中的表达(5.64±1.02)高于在癌旁组织中的表达(2.12±0.65);BCYRN1在卵巢癌细胞中的水平为SKOV3(2.25±0.78)、HO8910(2.85±0.78)、A27809(3.12±1.01)，显著高于IOSE(1.01±0.12);BCYRN1高表达能够促进SKOV3细胞的增殖、迁移和侵袭。 结论 BCYRN1在卵巢癌中表达上调，其作为促癌基因促进卵巢癌的进展。 -
关键词:
- LncRNA brain cytoplasmic RNA 1 /
- 卵巢癌 /
- SKOV3细胞株 /
- 增殖 /
- 转移
Abstract:Objective To investigate the expression of long chain non-coding RNA brain cytoplasmic RNA-1 (BCYRN1) in ovarian cancer and its effect on the malignant biological behaviour of SKOV3 cells. Methods A total of 32 ovarian cancer tissues and their corresponding adjacent tissues treated in Wenzhou Central Hospital from March 2017 to March 2019 were selected. Normal ovarian epithelial cell lines (IOSE) and ovarian cancer cell lines (SKOV3, HO8910, A2780) were purchased from ATCC. The level of BCYRN1 was detected by real-time PCR. SKOV3 cells were transfected with BCYRN1 high-expression plasmid and low-expression plasmid and their corresponding control substances, and cell lines with high and low expression of BCYRN1 were constructed. BrdU assay was used to detect cell proliferation, scratch healing test was used to detect cell migration, and Transwell assay was used to detect cell invasion. Results The expression of BCYRN1 in ovarian cancer tissues (5.64±1.02) was higher than that in adjacent tissues (2.12±0.65), and the levels of BCYRN1 in SKOV3, HO8910 and A27809 cells were (2.25±0.78), (2.85±0.78) and (3.12±1.01), respectively, which were significantly higher than those of IOSE (1.01±0.12). The high expression of BCYRN1 promoted the proliferation, migration and invasion of SKOV3 cells. Conclusion The expression of BCYRN1 is up-regulated in ovarian cancer, and it can be used as an oncogene to promote the progression of ovarian cancer. -
Key words:
- LncRNA brain cytoplasmic RNA-1 /
- Ovarian cancer /
- SKOV3 cell line /
- Proliferation /
- Metastasis
-
图 1 BCYRN1在卵巢癌组织和癌细胞中的表达
注：A采用qRT-PCR检测癌组织和癌旁组织中BCYRN1的相对表达水平(P < 0.001)。B采用qRT-PCR检测正常卵巢上皮细胞株(IOSE)和卵巢癌细胞株(SKOV3、HO8910、A27809)中BCYRN1的相对表达水平(与IOSE组比较，aP < 0.05)。
图 2 BCYRN1高表达和低表达对SKOV3细胞株增殖水平的影响
注：A为采用BrdU法检测BCYRN1高表达SKOV3细胞株的增殖; B为采用BrdU法检测BCYRN1低表达SKOV3细胞株的增殖。aP < 0.05。
图 3 BCYRN1高表达和低表达SKOV3株细胞的迁移水平
注：A、B为倒置显微镜下测定细胞穿过黑线迁移成像; C、D为细胞相对迁移面积用具体的数值量化。aP < 0.05。
-
[1] YOKOI A, MATSUZAKI J, YAMAMOTO Y, et al. Integrated extracellular microRNA profiling for ovarian cancer screening[J]. Nat Commun, 2018, 9(1): 4319. doi: 10.1038/s41467-018-06434-4 [2] MURALI R, GRISHAM R N, SOSLOW R A. The roles of pathology in targeted therapy of women with gynecologic cancers[J]. Gynecol Oncol, 2018, 148(1): 213-221. doi: 10.1016/j.ygyno.2017.11.020 [3] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67: 7-30. doi: 10.3322/caac.21387 [4] HOSKINS P J, GOTLIEB W H. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature[J]. CA Cancer J Clin, 2017, 67: 493-506. doi: 10.3322/caac.21408 [5] MOUFARRIJ S, DANDAPANI M, ARTHOFER E, et al. Epigenetic therapy for ovarian cancer: Promise and progress[J]. Clin Epigenetics, 2019, 11(1): 7. doi: 10.1186/s13148-018-0602-0 [6] LI W, MA S, BAI X, et al. Long noncoding RNA WDFY3-AS2 suppresses tumor progression by acting as a competing endogenous RNA of microRNA-18a in ovarian cancer[J]. J Cell Physiol, 2019, 235(2): 1141-1154. doi: 10.1002/jcp.29028 [7] KUMAR M M, GOYAL R. LncRNA as a therapeutic target for angiogenesis[J]. Curr Top Med Chem, 2017, 17(15): 1750-1757. doi: 10.2174/1568026617666161116144744 [8] WANG H, FU Z, DAI C, et al. LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer[J]. Sci Rep, 2016, 6(10): 38983. DOI: 10.1038/srep38983. [9] YU W, XIANG D, JIA H, et al. The lncRNA BCYRN1 Functions as an Oncogene in Human Glioma by Downregulating miR-125a-5p in vitro[J]. Cancer Manag Res, 2020, 12(4): 1151-1161. http://www.researchgate.net/publication/339220153_The_lncRNA_BCYRN1_Functions_as_an_Oncogene_in_Human_Glioma_by_Downregulating_miR-125a-5p_in_vitro [10] DING S, JIN Y, HAO Q, et al. LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connected with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis[J]. Cancer Cell Int, 2020, 20(3): 6. doi: 10.1186/s12935-019-1081-x [11] YU J H, CHEN Y. Clinical significance of lncRNA BCYRN1 in colorectal cancer and its role in cell metastasis[J]. Eur Rev Med Pharmacol Sci, 2019, 23(21): 9371-9378. http://www.ncbi.nlm.nih.gov/pubmed/31773686 [12] ZHAI H, LI Y. BCYRN1 is correlated with progression and prognosis in gastric cancer[J]. Biosci Rep, 2019, 39(11): BSR20190505. DOI: 10.1042/BSR20190505. [13] KOSSA M, LEARY A, SCOAZEC J Y, et al. Ovarian cancer: A heterogeneous disease[J]. Pathobiology, 2018, 85(1-2): 41-49. doi: 10.1159/000479006 [14] ZHANG Y, LI Y, WANG Q, et al. Identification of an lncRNA miRNA mRNA interaction mechanism in breast cancer based on bioinformatic analysis[J]. Mol Med Rep, 2017, 16(4): 5113-5120. doi: 10.3892/mmr.2017.7304 [15] WANG J C, SU Z L, LU S N, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer[J]. Clin Chim Acta. 2018, 485(4): 229-233. http://www.onacademic.com/detail/journal_1000040413707910_6b87.html [16] SHI X Y, SUN Y Z, LI M, et al. LncRNA CADM1-AS1 serves as a new prognostic biomarker for gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2019, 23(3): 232-238. http://www.ncbi.nlm.nih.gov/pubmed/31389606 [17] TANG J, YAN T, BAO Y, et al. LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc[J]. Nat Commun, 2019, 10(1): 3499. doi: 10.1038/s41467-019-11447-8 [18] QIU X, DONG J, ZHAO Z, et al. LncRNA LINC00668 promotes the progression of breast cancer by inhibiting apoptosis and accelerating cell cycle[J]. Onco Targets Ther, 2019, 12(43): 5615-5625. http://www.ncbi.nlm.nih.gov/pubmed/31371999 [19] DU W L, FENG Z J, SUN Q Q. LncRNA LINC00319 accelerates ovarian cancer progression through miR-423-5p/NACC1 pathway[J]. Biochem Biophys Res Commun, 2018, 507(1-4): 198-202. doi: 10.1016/j.bbrc.2018.11.006 [20] LONG X, SONG K, HU H, et al. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis[J]. J Exp Clin Cancer Res, 2019, 38(1): 345. doi: 10.1186/s13046-019-1329-2 [21] ZHUANG X H, LIU Y, LI J L. Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/beta-catenin signaling pathway[J]. Biosci Rep, 2019, 39(8): BSR20190906. DOI: 10.1042/BSR20190906. [22] WU Y, YU D, JUN Z, et al. Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer[J]. Cell Death Dis, 2018, 9(9): 861. doi: 10.1038/s41419-018-0908-z [23] LIANG H, YU T, HAN Y, et al. LncRNA PTAR promotes EMT and invasion‐metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression[J]. Mol Cancer, 2018, 17(1): 119. doi: 10.1186/s12943-018-0870-5 [24] SOSINSKA P, MIKULA-PIETRASIK J, KSIAZEK K. The double-edged sword of long non-coding RNA: The role of human brain-specific BC200 RNA in translational control, neurodegenerative diseases, and cancer[J]. Mutat Res Rev Mutat Res, 2015, 766(10): 58-67. http://www.sciencedirect.com/science/article/pii/S1383574215000630 [25] HU T, LU Y R. BCYRN1, a c-MYC-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer[J]. Cancer Cell Int, 2015, 15(2): 36. http://pdfs.semanticscholar.org/e3bf/2c072420f190019edae9c9fa7354af62198f.pdf [26] WANG Y, BAI W, WANG M, et al. Long non-coding RNA brain cytoplasmic RNA 1 acts as an oncogene and regulates cell proliferation and metastasis in non-small cell lung cancer[J]. J Nanosci Nanotechnol, 2019, 19(4): 1978-1985. doi: 10.1166/jnn.2019.16402 [27] IACOANGELI A, ADZOVIC L, CHEN E Q, et al. Regulatory BC200 RNA in peripheral blood of patients with invasive breast cancer[J]. J Investig Med, 2018, 66(7): 1055-1063. doi: 10.1136/jim-2018-000717 [28] IACOANGELI A, LIN Y, MORLEY E J, et al. BC200 RNA in invasive and preinvasive breast cancer[J]. Carcinogenesis, 2005, 25(2): 2125-2133. [29] ZHAO R H, ZHU C H, LI X K, et al. BC200 LncRNA a potential predictive marker of poor prognosis in esophageal squamous cell carcinoma patients[J]. Onco Targets Ther, 2016, 9(8): 2221-2226. http://pdfs.semanticscholar.org/192e/eb5d23eec52f6c25fdd7c3751103aff78635.pdf [30] GU L, LU L, ZHOU D, et al. Long noncoding RNA BCYRN1 promotes the proliferation of colorectal cancer cells via up-regulating NPR3 expression[J]. Cell Physiol Biochem, 2018, 48(10): 2337-2349. http://www.karger.com/Article/Pdf/492649 [31] PENG J, HOU F, FENG J, et al. Long non-coding RNA BCYRN1 promotes the proliferation and metastasis of cervical cancer via targeting microRNA-138 in vitro and in vivo[J]. Oncol Lett, 2018, 15(1): 5809-5818. http://www.onacademic.com/detail/journal_1000040283511910_455c.html [32] KRAUS T F, GREINER A, GUIBOURT V, et al. Identification of stably expressed lncRNAs as valid endogenous controls for profiling of human glioma[J]. J Cancer, 2015, 6(1): 111-119. http://europepmc.org/articles/PMC4280393/pdf/jcav06p0111.pdf -
下载:
点击查看大图
图(4)
计量
- 文章访问数: 118
- HTML全文浏览量: 74
- PDF下载量: 1
- 被引次数: 0
